US Nuclear Medicine Market worth $9.56 billion by 2030
The report "US Nuclear Medicine Market by Type (SPECT [Tc99m, I-123, Ga-67], PET [F-18], Alpha Emitters, Beta Emitters [Y-90, Lu-177]), Application (Onco, Neuro), Procedure, End User (Imaging Center, Hospital), Radioisotope, Market Share, Growth - Forecast to 2030", is projected to reach USD 9.56 billion by 2030 from USD 4.81 billion in 2025, at a high CAGR of 14.7% during the forecast period.
Browse 170 market data Tables and 10 Figures spread through 250 Pages and in-depth TOC on "US Nuclear Medicine Market by Type (SPECT [Tc99m, I-123, Ga-67], PET [F-18], Alpha Emitters, Beta Emitters [Y-90, Lu-177]), Application (Onco, Neuro), Procedure, End User (Imaging Center, Hospital), Radioisotope, Market Share, Growth - Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/us-nuclear-medicine-market-81855094.html
The rapid development of the theranostics strategies and commercialization of next-generation radioligand therapies in the US healthcare system contribute to the US nuclear medicine market growth. Additionally, favorable reimbursement models, strong clinical research, and expedited regulatory processes with new radiotracers are accelerating rapid adoption. Further investments in the domestic radioisotopes production, development of nuclear pharmacy, and automation technologies continue to improve the stability of supplies and operational efficiency throughout the US nuclear medicine ecosystem.
“The diagnostic nuclear medicine segment accounted for the largest share of the US nuclear medicine market, by type.”
In 2024, the diagnostic nuclear medicine segment accounted for the largest share of the US nuclear medicine market. This is due to its routine integration into regular clinical processes and the large volume of procedures in hospitals and outpatient imaging centers. Segment dominance has also been facilitated by the wide accessibility of FDA-approved diagnostic radiopharmaceuticals; standard reimbursement strategies and the extensive nuclear pharmacy network ensure reliable access to short half-life radioisotopes. Additionally, ongoing improvements in the imaging hardware and software have strengthened the extensive clinical dependence on diagnostic nuclear medicine in the US.
“The hospitals segment is the fastest-growing segment during the forecast period, by end user.”
In 2024, the hospitals segment is expected to register the fastest growth during the forecast period. This growth is due to the expansion of nuclear medicine departments within hospitals, the installation of advanced PET and SPECT systems, and hospitals becoming an important center of radiopharmaceutical therapies and theranostics procedures. Moreover, a growing demand by US hospitals to support on-site or collaborative nuclear pharmacy services to ensure timely access to radioisotopes is supported by favorable reimbursement policies and strong clinical research activity.
Key Players
The key players functioning in the US nuclear medicine market include GE HealthCare (US), Cardinal Health (US), Curium (France), Bayer AG (Germany), Lantheus Holdings, Inc. (US), Novartis AG (Switzerland), Jubilant Pharmova Limited (India), Bracco Imaging S.P.A (Italy), Pharmalogic Holdings Corp. (US), Sun Pharmaceutical Industries, Inc. (India), Nordion Inc. (Canada), Siemens Healthineers AG (Germany), NorthStar Medical Radiosiotopes, LLC (US), Eckert & Ziegler (Germany), Actinium Pharmaceuticals, Inc. (US), Global Medical Solutions (US), Telix Pharmaceuticals Limited (Australia), PDRadiopharma Inc. (Japan), ITM Isotope Technologies Munich SE (Germany), BWX Technologies Inc. (US), SHINE Technologies, LLC (US), Isotopia (Israel), IRE Elit (Turkey), Cyclopharm (Australia), and RadioMedix, Inc. (US).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the US Nuclear Medicine Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
